Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer

Seminars in Oncology

Volumn 42, Issue , 2015, Pages S3-S10

  Pennell, Nathan A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG TREATMENT FAILURE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IN VIVO STUDY; INNATE IMMUNITY; NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; PROCEDURES; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG APPROVAL; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84944752909     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.09.016     Document Type: Review

References (56)

1. E. Jonasch, and F.G. Haluska Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities Oncologist 6 2001 34 55
2. W.B. Coley May 1893. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases Am J Med Sci 105 1893 487 511
3. C.A. Janeway Jr, P. Travers, M. Walport, and M.J. Shlomchik Immunobiology 5th ed. 2001 Garland Publishing New York
4. A.L. St John, and S.N. Abraham Innate immunity and its regulation by mast cells J Immunol 190 2013 4458 4463
5. D. Mittal, M.M. Gubin, R.D. Schreiber, and M.J. Smyth New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape Curr Opin Immunol 27 2014 16 25
6. The Jackson Laboratory. Immunodeficient JAX(R) mice models. Available at: http://jaxmice.jax.org/literature/factsheet/FS0066-immunodeficient-JAXMiceModels.pdf. Accessed June 5, 2015.
7. C.U. Kirchgessner, C.K. Patil, J.W. Evans, and et al. DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect Science 267 1995 1178 1183
8. B. Zhang, Z. Duan, and Y. Zhao Mouse models with human immunity and their application in biomedical research J Cell Mol Med 13 2009 1043 1058
9. T. Berney, R.D. Molano, A. Pileggi, and et al. Patterns of engraftment in different strains of immunodeficient mice reconstituted with human peripheral blood lymphocytes Transplantation 73 2001 133 140
10. L.D. Shultz, P.A. Schweitzer, S.W. Christianson, and et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice J Immunol 154 1995 180 191
11. S. Kataoka, J. Satoh, H. Fujiya, and et al. Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity Diabetes 32 1983 247 253
12. D.L. Greiner, L.D. Shultz, J. Yates, and et al. Improved engraftment of human spleen cells in NOD/LtSz-SCID mice as compared with C.B-17-SCID/SCID mice Am J Pathol 146 1995 888 902
13. W.J. Leonard Cytokines and immunodeficiency diseases Nat Rev Immunol 1 2001 200 208
14. A. Puel, S.F. Ziegler, R.H. Buckley, and W.J. Leonard Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency Nat Genet 20 1998 394 397
15. C.M. Vajdic, and M.T. van Leeuwen Cancer incidence and risk factors after solid organ transplantation Int J Cancer 125 2009 1747 1754
16. A.E. Grulich, M.T. van Leeuwen, M.O. Falster, and C.M. Vajdic Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis Lancet 370 2007 59 67
17. H. Kappauf, W.M. Gallmeier, P.H. Wunsch, and et al. Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer. Case report, review of the literature, and discussion of possible biological pathways involved Ann Oncol 8 1997 1031 1039
18. R.J. Papac Spontaneous regression of cancer: Possible mechanisms In Vivo 12 1998 571 578
19. J.A. Thomas, and M. Badini The role of innate immunity in spontaneous regression of cancer Indian J Cancer 48 2011 246 251
20. S.A. Hopton Cann, J.P. van Netten, and C. van Netten Dr William Coley and tumor regression: a place in history or in the future Postgrad Med J 79 2003 672 680
21. T. Jessy Immunity over inability: The spontaneous regression of cancer J Nat Sci Biol Med 2 2011 43 49
22. J.P. Dutcher Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma Oncology (Williston Park) 16 11 Suppl 13 2002 4 10
23. L. Ridolfi, O. Bertetto, A. Santo, and et al. Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial Int J Oncol 39 2011 1011 1017
24. A. Ardizzoni, F. Salvati, R. Rosso, and et al. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report The Italian Lung Cancer Task Force. Cancer 72 1993 2929 2935
25. L.H. Maurer, T. Pajak, W. Eaton, and et al. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: A phase III cancer and Leukemia Group B Study J Clin Oncol 3 1985 969 976
26. R.A. Matthay, D.A. Mahler, G.J. Beck, and et al. Intratumoral bacillus Calmette-Guerin immunotherapy prior to surgery for carcinoma of the lung: results of a prospective randomized trial Cancer Res 46 1986 5963 5968
27. D. Atanackovic, N.K. Altorki, E. Stockert, and et al. Vaccine-induced CD4+T cell responses to MAGE-3 protein in lung cancer patients J Immunol 172 2004 3289 3296
28. K. Sigel, J. Wisnivesky, K. Gordon, and et al. HIV as an independent risk factor for incident lung cancer AIDS 26 2012 1017 1025
29. M.E. O'Brien, H. Anderson, E. Kaukel, et al.; on behalf of the SR-ON-12 Study Group SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results Ann Oncol 15 2004 906 914
30. C. Butts, M.A. Socinski, P.L. Mitchell, and et al. on behalf of the START Trial Team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial Lancet Oncol 15 2014 59 68
31. J.F. Vansteenkiste, B. Cho, T. Vanakesa, and et al. MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGO-A3+AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC) Ann Oncol 25 suppl 4 2014 Abstract 1173O
32. ® vaccine in advanced-stage non-small-cell lung cancer Cancer Gene Ther 13 2006 555 562
33. G. Giaccone, L. Bazhenova, J. Nemunaitis, and et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small cell lung cancer (NSCLC) Eur J Cancer 49 Suppl 3 2013 Abstract LBA2
34. S. Ramalingam, J. Crawford, A. Chang, and et al. on behalf of the FORTIS-M Study Investigators. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) Ann Oncol 24 2013 2875 2880
35. C. Manegold, N. van Zandwijk, A. Szczesna, and et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer Ann Oncol 2 2012 72 77
36. H. Winter, N.K. van den Engel, M. Rusan, and et al. Active-specific immunotherapy for non-small cell lung cancer J Thorac Dis 3 2011 105 114
37. M.E. O'Brien, A. Sani, I.E. Smith, and et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma Br J Cancer 83 2000 853 857
38. J.L. Stanford, C.A. Stanford, M.E. O'Brien, and J.M. Grange Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung Eur J Cancer 44 2008 224 227
39. C. Butts, A. Maksymiuk, G. Goss, and et al. A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for the active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01 J Thor Oncol 2 2007 s332 s333
40. C. Butts, R.N. Murray, C.J. Smith, and et al. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer Clin Lung Cancer 11 2010 391 395
41. J. Vansteenkiste, M. Zielinski, A. Linder, and et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC) J Clin Oncol 25 18S 2007 Abstract 7554
42. R. Salga, T. Lynch, A. Skarin, and et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating tumor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma J Clin Oncol 21 2003 624 630
43. J. Nemunaitis, D. Sterman, D. Jablons, and et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer J Natl Cancer Inst 96 2004 326 331
44. J. Nemunaitis, R.O. Dillman, P.O. Schwarzenberger, and et al. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer J Clin Oncol 24 2006 4721 4730
45. P. Serafini, R. Carbley, K.A. Noonan, G. Tan, V. Bronte, and I. Borrello High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells Cancer Res 64 2004 6337 6343
46. E.A. Quoix, F. Forget, Z. Papai-Szekely, and et al. Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy J Clin Oncol 33 suppl 2015 Abstract 3034
47. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
48. C. Robert, G.V. Long, B. Brady, C. Dutriaux, M. Maio, and L. Mortier Nivolumab in previously untreated melanoma without BRAF mutation N Engl J Med 372 2015 320 330
49. C. Robert, J. Schachter, G.V. Long, and et al. KEYNOTE-006 Investigators. Pembrolizumab versus ipilimumab in advanced melanoma N Engl J Med 372 2015 2521 2532
50. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
51. J.S. Weber, S. O'Day, W. Urba, and et al. Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 2008 5950 5956
52. J.C. Yang, M. Hughes, U. Kammula, and et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis J Immunother 30 2007 825 830
53. A.J. van den Eertwegh, J. Versluis, H.P. van den Berg, and et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial Lancet Oncol 13 2012 509 517
54. B. Carthon, J.D. Wolchok, J. Yuan, and et al. Pre-operative CTLA-4 blockade: tolerability and immune monitoring in the setting of a pre-surgical clinical trial Clin Cancer Res 16 2010 2861 2871
55. F.S. Hodi, M. Butler, D.A. Oble, and et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients Proc Natl Acad Sci U S A 105 2008 3005 3010
56. G.V. Scagliotti, P. Bironzo, and J.F. Vansteenkiste Addressing the unmet need in lung cancer: the potential of immuno-oncology Cancer Treat Rev 41 2015 465 475